Literature DB >> 20214589

Hypersensitivity reactions to non-steroidal anti-inflammatory drugs.

José Antonio Cornejo-Garcia1, Natalia Blanca-López, Inmaculada Doña, Inmaculada Andreu, José A G Agúndez, Miguel Carballo, Miguel Blanca, María Gabriela Canto.   

Abstract

NSAIDs are the most important group of drugs involved in hypersensitivity drug reactions, and include heterogeneous compounds with very different chemical structures. These reactions can be IgE dependent (immediate reactions), T cell-mediated (non-immediate), or induced by a non-specific immunological mechanism related with the blocking of the COX-1 enzyme and the shunting to the lipooxygenase pathway (cross-intolerant reactions). Cutaneous symptoms are the most frequent, with ibuprofen, naproxen and diclofenac being common culprit drugs worldwide, although others can be involved because patterns of consumption and exposure rates vary between countries. A very important proportion of immunological reactions are immediate, with urticaria and anaphylaxis being the typical clinical manifestations. Non-immediate reactions comprise a number of heterogeneous entities ranging from mild exanthema to severe TEN or DRESS syndrome, as well as organ-specific reactions such as hepatitis or pneumonitis. Cross-intolerant reactions appear to non-chemically related drugs, and involve respiratory airways, skin or both. In vivo diagnostic tests are based on the capacity of the skin to respond to the culprit drug, but their sensitivity is in many instances rather low. The approach for in vitro testing consists of either detecting specific IgE antibodies or studying the proliferation of T lymphocytes toward the eliciting drug. No appropriate tests are yet available for the in vitro validation of cross-intolerance reactions, although techniques based on the stimulation of basophils have been proposed. Based on these findings, the diagnostic approach is often based on the controlled administration of the drug to assess tolerance. In this work we review current knowledge on hypersensitivity reactions to NSAIDs, including diagnostic approach and genetic studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20214589     DOI: 10.2174/138920009790711841

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  6 in total

1.  Safe administration of celecoxib to a patient with repeated episodes of nephrotic syndrome induced by NSAIDs.

Authors:  Karlo Mihovilovic; Danica Ljubanovic; Mladen Knotek
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  Common UGT1A6 Variant Alleles Determine Acetaminophen Pharmacokinetics in Man.

Authors:  María de Las Olas Cerezo-Arias; Javier Gómez-Tabales; Manuel Martí; Elena García-Martín; José A G Agúndez
Journal:  J Pers Med       Date:  2022-04-29

3.  FCERI and Histamine Metabolism Gene Variability in Selective Responders to NSAIDS.

Authors:  Gemma Amo; José A Cornejo-García; Jesus M García-Menaya; Concepcion Cordobes; M J Torres; Gara Esguevillas; Cristobalina Mayorga; Carmen Martinez; Natalia Blanca-Lopez; Gabriela Canto; Alfonso Ramos; Miguel Blanca; José A G Agúndez; Elena García-Martín
Journal:  Front Pharmacol       Date:  2016-09-29       Impact factor: 5.810

4.  Asthma and Rhinitis Induced by Selective Immediate Reactions to Paracetamol and Non-steroidal Anti-inflammatory Drugs in Aspirin Tolerant Subjects.

Authors:  Diana Pérez-Alzate; Natalia Blanca-López; Inmaculada Doña; José A Agúndez; Elena García-Martín; José A Cornejo-García; James R Perkins; Miguel Blanca; Gabriela Canto
Journal:  Front Pharmacol       Date:  2016-07-20       Impact factor: 5.810

5.  Pyrazolones metabolites are relevant for identifying selective anaphylaxis to metamizole.

Authors:  Adriana Ariza; Elena García-Martín; María Salas; María I Montañez; Cristobalina Mayorga; Natalia Blanca-Lopez; Inmaculada Andreu; James Perkins; Miguel Blanca; José A G Agúndez; María J Torres
Journal:  Sci Rep       Date:  2016-03-31       Impact factor: 4.379

6.  Type B adverse drug reactions reported by an immunoallergology department.

Authors:  Maria J Costa; Maria T Herdeiro; Jorge J Polónia; Inês Ribeiro-Vaz; Cármen Botelho; Eunice Castro; Josefina Cernadas
Journal:  Pharm Pract (Granada)       Date:  2018-03-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.